Thursday, August 2, 2018
#Cannabisstocks - ALGAE DYNAMICS CORP (OTC: $ADYNF) SECURES BULK #CANNABIS SUPPLY AGREEMENT FOR COLLABORATION PARTNERS
#Cannabisstocks - ALGAE DYNAMICS CORP (OTC: $ADYNF)
SECURES BULK #CANNABIS SUPPLY AGREEMENT FOR COLLABORATION PARTNERS
TORONTO, Aug. 02, 2018 –(Investorideas.com Newswire) ALGAE DYNAMICS CORP (OTC: ADYNF) (the
"Company"), a company focused on the development of unique health
products and nutraceuticals utilizing cannabis and botanical oil extracts, has
secured a supply agreement to enable Canadian Licensed Producers and
International Licensed Importers access to bulk cannabis deliveries in
anticipation of licensing agreements for our proprietary Cannabis formulated
products.
Read this in full at http://www.investorideas.com/news/2018/cannabis/08021OTCADYNF.asp
Recent Developments in our Collaboration with Western University
The researchers at Western University, the Company’s
scientific collaboration team, have developed a very unique formulation
involving cannabis and other botanical extracts. Western University’s Dr.
Laviolette said, “We are pleased to report significant progress on our ongoing
projects with Algae Dynamics. We are continuing to work out the precise
molecular mechanisms underlying the therapeutic modes of action for several
unique cannabinoid formulations. These research projects are identifying safer
and clinically superior cannabinoid formulations aimed at treating the symptoms
of various psychiatric disorders, while eliminating the negative side effects
associated with traditional marijuana formats.”
The invention will be assigned to Algae Dynamics Corp.
free from any royalties and will become 100% owned by the company.
We are in the process of filing a patent application
prior to entering into domestic and international distribution agreements with
Licensed Producers/Dealers (LPs/LDs) and Pharmaceutical companies.
Our discussions with the perspective LP’s/LD’s have
included the production, distribution and related collaborative initiatives
involving our specially formulated products.
We have an assignable supply agreement with a
large-volume, high-quality cannabis grower to secure a source of cannabis
material for our Licensed Partners producing and selling our Medical Cannabis
formulations.
We expect to generate revenue in 2018 from our
agreements with our Licensed Partners.
Paul Ramsay stated, “We are pleased that we can
further support Dr. Steven Laviolette and his team at Western University by
securing a high-quality and high-volume supply of Medical Cannabis for
formulations applicable to mental health conditions.”
About Dr. Steven Laviolette
The investigator leading the research is Dr. Steven
Laviolette, a Professor and Neuroscientist in the Schulich School of Medicine
& Dentistry at Western University in London, Ontario. Dr. Laviolette is a
leader in the study of cannabinoids in mental health and was recently awarded
“Faculty Scholar” status at Western University. Dr. Laviolette’s research team
has previously made numerous fundamental discoveries related to how
cannabinoids impact and may serve as treatments for mental health disorders
including schizophrenia, depression, post-traumatic stress disorder and
anxiety. Dr. Laviolette’s primary research focus is in characterizing how
specific phytochemical derivatives of cannabis may interact with specific brain
pathways and molecular mechanisms whereby they may improve symptoms associated
with various mental health disorders. Research from Dr. Laviolette’s team has
been published in the top neuroscience and psychiatry journals in the world.
His full profile may be seen on Western University’s, website www.uwo.ca
About Algae Dynamics Corp (ADC)
ADC is engaged in the development of unique health
products and nutraceuticals that utilize hemp, cannabis and algae oils. We have
engaged two Canadian universities to provide research into the use of extracts
from cannabis oil, which we plan to use to develop products that combine the
significant health benefits of Omega-3s derived from algae oil and extracts
from cannabis oil. Our research is focused on the use of cannabis oil in the
context of cancer, and the use of cannabis derivatives for the development of
novel pharmacotherapies for mental health.
For more information, visit http://www.algaedynamics.com
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking
statements" as that term is defined in Section 27A of the Securities Act
and Section 21E of the Securities Exchange Act of 1934, as amended. Statements
in this press release which are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans, expectations or
intentions regarding the future. Such forward-looking statements include, among
other things, use of proceeds and the development, costs and results of current
or future actions and opportunities in the sector. Actual results could differ
from those projected in any forward-looking statements due to numerous factors.
Such factors include, among others, the inherent uncertainties associated with
new projects and development stage companies, our ability to raise the
additional funding we will need to continue to pursue our exploration and
development program, and our ability to retain important members of our
management team and attract other qualified personnel. These forward-looking
statements are made as of the date of this news release, and we assume no
obligation to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans, expectations and
intentions contained in this press release are reasonable, there can be no
assurance that any such beliefs, plans, expectations or intentions will prove
to be accurate.
Investors should consult all the information set forth
herein and should also refer to the risk factors disclosure outlined in our
annual report on Form 10-K for the most recent fiscal year, our quarterly
reports on Form 10-Q and other periodic reports filed from time-to-time with
the Securities and Exchange Commission.
This news is
published on the Investorideas.com Newswire - a global digital news source for
investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated for
news publication and distribution, social media and marketing, content creation
and more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/
Additional info regarding BC
Residents and global Investors: Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for more
info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Please read Investorideas.com
privacy policy: http://www.investorideas.com/About/Private_Policy.asp
Wednesday, August 1, 2018
Investorideas.com - #Cannabisstocks: Sproutly (CSE:SPR) Closes Acquisition of Infusion Biosciences Canada and SSM
Investorideas.com - #Cannabisstocks: Sproutly (CSE:SPR) Closes Acquisition of Infusion Biosciences Canada and SSM
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investorideas.com - #Cannabisstocks: Sproutly (CSE:SPR) Closes Acquisition of Infusion Biosciences Canada and SSM
Investorideas.com - #Cannabisstocks: Sproutly (CSE:SPR) Closes Acquisition of Infusion Biosciences Canada and SSM
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investorideas.com - #Cannabisstocks: Canopy Growth Corporation (TSX: $WEED.TO, NYSE: $CGC) to Announce First Quarter Fiscal 2019 Financial Results
Investorideas.com - #Cannabisstocks: Canopy Growth Corporation (TSX: $WEED.TO, NYSE: $CGC) to Announce First Quarter Fiscal 2019 Financial Results
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: CEO of Lexaria Biosciences Corp (CSE: $LXX.C) (OTC: $LXRP) Talks about Drug Delivery Platform, Hill Street Beverage Deal and Human Clinical Trial Results
Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move: CEO of Lexaria Biosciences Corp (CSE: $LXX.C) (OTC: $LXRP) Talks about Drug Delivery
Platform, Hill Street Beverage Deal
and Human Clinical Trial Results
Delta, Kelowna, BC –August 1, 2018 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca release today’s edition of its series, Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at http://www.investorideas.com/news/2018/cannabis/08011Potcasts-CSELXX-CEO.asp
Today’s podcast overview/transcript:
Good morning and welcome to another Investorideas.com potcast – looking
at cannabis news, stocks to watch as well as insights from thought leaders and
experts.
Today I will be talking with Chris Bunka the CEO of Lexaria Biosciences
Corp. trading on the CSE as LXX and the OTC as LXRP.
Lexaria has developed a new disruptive drug delivery platform:
DehydraTECH The Company’s patented technology changes the way Active
Pharmaceutical Ingredients (“APIs”) enter the body orally by masking unwanted
tastes, reducing the time of onset, avoiding first-pass liver metabolism and
increasing bio-absorption by 5-10X.
Interview highlights:
Q:Investorideas.com
Can you explain in simple terms how the company’s delivery technology
DehydraTECH™ works and some of the applications for the technology?
Chris Bunka:
“Our technology can be thought of as a dinner plate, we make a high-tech
dinner plate. What you put on that is up to you. Our plate helps to pile that
drug on and get it into your body more effectively. Our tech is based on some
well-known bio chemistry which it’s the body’s propensity to absorb long chain
fatty acids, similar to sunflower oil or avocado oil. We then “crazy glue” the
long chain fatty acid to the side of the API. When you use our tech, you smell
and taste the oleic acid, which has no taste and smell and masks the smell and
taste of, in this case cannabinoids.”
Q: Investorideas.com
Your company has issued and pending patents in over 40 countries around
the world. That is impressive and somewhat unusual to find in a company
of your size, so can you talk about your Intellectual property and licensing
strategy?
Chris Bunka:
“We have 49 patents pending in 43 countries around the world and 8
patents granted with regards to DehydraTECH. We’re a small company but we punch
above our weight. We are perhaps the only company our size that has completed
all in vitro, in vivo and human clinical studies. We recently released a human
clinical study that was conducted in Europe using our turbo CBD hemp oil
product. In that study we demonstrated that we are able to deliver much more
cannabidiol into a human being and much more quickly. We compared the data to a
previous study done by Mount Sinai Hospital with a cannabidiol provided by GW
Pharmaceuticals (NASDAQ: GWPH) . At the 30-minute mark, using our turbo CBD,
we had over 900% more cannabidiol in blood then they did.”
Recent news:
Significant Bioavailability
Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered
TurboCBD (TM) Capsules
Q: Investorideas.com
The company is forming four new wholly-owned subsidiaries, one each for
the pharmaceutical, nicotine, hemp, and cannabis industries. Can you talk about
this strategy and what it means for the bigger picture?
Chris Bunka:
“We realize that companies in the
pharmaceutical industry or the nicotine industry even today may not want to
have any association to the cannabis industry, which was one of the reasons we
wanted to build a fence around our different intellectual property assets. We
think this also a good deal for our shareholders as it gives us the opportunity
to take those subsidiaries down slightly different paths with separate
financing which adds versatility to the company, minimizes shareholder dilution
and helps us conduct business with a broader swath of fortune 500 and global
companies.”
Q: Investorideas.com
On your website you say the legal cannabinoid consumer products space is
expected to show Compounded Annual Growth Rate of more than 25% through 2021 in
North America. Do you see that increasing based on federal legalization
here this fall and the push for federal legalization in the US? And where
do you see this industry ten years out ?
Chris Bunka:
“The general answer is yes. I
think the growth rates for cannabinoids edibles is going to be strongly double
digit for the next years to come. I think as the market matures to embrace the
“fat part’ of the demand curve, you’re going to see huge growth in
consumer-friendly methods of ingesting cannabis. I don’t think most people
realize we are in the first or second inning. You’re going to need the
development of edibles legislation, international markets, international
acceptance and societal acceptance. I wouldn’t be surprise to see double digit
growth for a decade or more and in ten years I wouldn’t be surprise to see
cannabis industry bigger then beer or wine.”
Recent news : Lexaria Bioscience and Hill
Street Beverage Company Announce Definitive Agreement for Cannabis-Infused
Beverages
If you would like to be a guest or sponsor this podcast contact
Investorideas.com
Investor ideas reminds
all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Lexaria Bioscience Corp. has developed and
out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria's technology
provides increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on
iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, iHeartradio and
Tunein.
Potcasts is now a certified word
mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires
Big Investing Ideas
Investorideas.com is a recognized news source
publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and
stock news column, Investor
Ideas #Potcasts #Cannabis News and
Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the Stock Guru daily podcast on Support and Resistance Trading.
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria
Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast
starting July 5 2018 more info
http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with Sedar.
Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Do you trade or invest in Marijuana / Hemp
Stocks? Check out our stock directory of
publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX
Marijuana / Hemp Stocks
Join our Group on Linkedin and talk about - Marijuana / Hemp Stocks - News and Trends in Green Investing
Subscribe to:
Posts (Atom)